Denali therapeutics announces first human biomarker proof of concept for its transport vehicle (tv) technology achieved in phase 1/2 study of etv:ids (dnl310) in hunter syndrome (mps ii)

South san francisco, calif., nov. 10, 2020 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced biomarker proof of concept was achieved for its transport vehicle (tv) technology in a phase 1/2 study of etv:ids (dnl310) for the potential treatment of hunter syndrome (mps ii). denali's tv platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes, proteins, and oligonucleotides across the bbb after intravenous administration.
DNLI Ratings Summary
DNLI Quant Ranking